This means that even though there's a non-narcotic, non-addictive medication that can reverse overdoses – naloxone – that is so effective against opiates the American Medical Association recommends co-prescribing it with any opiate-based medication, you can't assume that first responders approaching an overdose victim will have it with them.
Patients who terminated the study early, before week 16, or did not have sufficient data for assessment at week 16 were considered non-responders (non-responder imputation approach); last-observation-carried-forward methodology was used for the sensitivity analysis.
By focusing on differences in dynamic changes on RNA and/or protein expression profiles between responders and non-responders, this approach should detect markers of resistance to Herceptin and/or mechanisms causally associated with the resistant phenotype.
For categorical clinical and functional outcomes, a non-responder imputation approach was used, such that patients with missing responses were considered non-responders.
Non-responders were approached repeatedly via telephone, text message and email.
If we did not get a response in two to 3 weeks, non-responders were approached in lecture rooms and training sessions to ask them to complete the questionnaire.
With our approach (responder analysis based on percentage change from baseline) this was not generally the case with less simple outcomes, including fatigue, Fibromyalgia Impact Questionnaire scores, anxiety, depression, and most domains of SF-36, apart perhaps vitality.
According to the prevalence approach, responder patients were 68.6% in the mesalazine group versus 67.4% in the placebo group, with a δ difference in favour of the mesalazine group of 1.2% (p=0.870; 95% CI −12.8% to 15.1%) (figure 3B).
According to the prevalence approach, responder patients were 66.3% in the mesalazine group versus 61.6% in the placebo group, with a δ in favour of the mesalazine group of 4.7% (p=0.525; 95% CI −9.7%too 19.0%) (figure 4B).
